Mednet Logo
HomeOphthalmologyQuestion

How do you decide whether to continue hydroxychloroquine in a young patient who develops subretinal neovascularization with no other risk factors?

1 Answers
Mednet Member
Mednet Member
Ophthalmology · New Jersey Medical School, Rutgers University

Hydroxychloroquine (HCQ), an anti-inflammatory and immunomodulatory agent, is used to treat autoimmune diseases (rheumatoid arthritis, lupus, Sjogren’s disease, etc.) and malarial prophylaxis. Vision problems can ensue resulting from these deleterious irreversible effects of HCQ on retina if the cum...

Register or Sign In to see full answer

How do you decide whether to continue hydroxychloroquine in a young patient who develops subretinal neovascularization with no other risk factors? | Mednet